Related Experiment Video
Updated: Jul 26, 2025
Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
Published on: August 30, 2014
Specific Immunotherapy and Follow-up Management of Respiratory Allergic Diseases in Children
Insights
Specific immunotherapy significantly improves asthma control in children by reducing symptoms and enhancing lung function. This safe and effective treatment offers superior clinical efficacy for allergic bronchial asthma management.
Area of Science:
- Pediatric Allergy and Immunology
- Respiratory Medicine
- Immunotherapy Research
Background:
- Allergic bronchial asthma is a common respiratory condition in children.
- Effective management strategies are crucial for improving quality of life and long-term outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of specific immunotherapy versus routine care for pediatric allergic bronchial asthma.
Main Methods:
- 100 children with allergic bronchial asthma were randomized into specific immunotherapy or routine treatment groups.
- Outcomes assessed included symptom control, pulmonary function, immune markers, inflammatory factors, and adverse events.
Main Results:
- Specific immunotherapy significantly reduced asthma symptoms and improved pulmonary function (FEV1/FVC, PEF%).
- Immunotherapy modulated immune cell levels (CD3+, CD4+, CD4+/CD8+, CD8+) and decreased inflammatory factors (IL-4, IL-12).
- Higher clinical efficacy was observed with specific immunotherapy, with a similar incidence of adverse reactions compared to routine care.
Conclusions:
- Specific immunotherapy is a safe and effective treatment for children with allergic bronchial asthma.
- It offers significant benefits in symptom control, lung function, and immune response.
- Specific immunotherapy warrants wider adoption in clinical practice.
Objective:
To analyze specific immunotherapy and follow-up management for respiratory allergic diseases in children.
Methods:
A total of 100 children with allergic bronchial asthma admitted to our hospital from November 2020 to October 2021 were selected. Based on different treatment schemes, they were divided into two groups: the routine treatment group and the immunotherapy group, with 50 cases in each group. The routine treatment group received standard care, while the immunotherapy group underwent specific immunotherapy. Assessment parameters included asthma symptom control score, pulmonary function, immune function, levels of inflammatory factors, clinical efficacy, and adverse reactions.
Results:
After treatment and during follow-up, the immunotherapy group showed significantly lower scores for daytime and nighttime symptoms compared to the routine treatment group (P < .05). The immunotherapy group also exhibited higher FEV1/FVC and PEF% values compared to the routine therapy group after treatment and at follow-up (P < .05). Furthermore, the immunotherapy group showed higher levels of CD3+, CD4+, and CD4+/CD8+ and lower levels of CD8+ compared to the routine therapy group (P < .05). Additionally, the immunotherapy group demonstrated lower levels of IL-4 and IL-12 compared to the routine therapy group after treatment and during follow-up (P < .05). The total effective rate of the immunotherapy group was higher than that of the routine therapy group (P < .05). The incidence of adverse reactions in the immunotherapy group was similar to that in the routine therapy group (P > .05).
Conclusions:
Specific immunotherapy is a significantly effective approach to managing children's allergic bronchial asthma. It effectively controls asthma symptoms, improves lung function and immune response, and reduces inflammatory factors. It showed superior clinical efficacy and minimal adverse reactions; specific immunotherapy, therefore, is a safe and beneficial treatment option that warrants further promotion and application.
Related Concept Videos
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:30Asthma-IV: Nursing Management
First, in...
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
02:06Allergic Reactions